Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 2Carcinoma, Renal Cell 2Urothelial Cancer 1Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 4Cisplatin 4pembrolizumab 3Carboplatin 3erdafitinib 2durvalumab 2vinflunine 1tremelimumab 1niraparib 1enfortumab vedotin 1cabozantinib 1avelumab 1atezolizumab 1Tiragolumab 1Sunitinib 1Radiotherapy 1Radiation Dose Hypofractionation 1Paclitaxel 1Nivolumab 1Midazolam 1Metformin 1Ipilimumab 1Everolimus 1Docetaxel 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urothelial Cancer × Tiragolumab × Genitourinary × Clear all
NCT05645692 2026-04-29

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Hoffmann-La Roche

Phase 2 Active not recruiting
204 enrolled
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡